Abstract
Purpose Physical activity within the hospital post-stroke is recommended for cardiovascular and musculoskeletal health, but no studies have examined cerebrovascular health. We hypothesized individuals who walked farther distances (FARhigh) in the hospital would have a higher resting middle cerebral artery blood velocity (MCAv) and a greater cerebrovascular response (CVR) to moderate-intensity exercise at 3-months post-stroke, compared to individuals who walked shorter distances (FARlow).
Methods At 3-month post-stroke, we recorded 90-seconds of baseline (BL) MCAv followed by 6-minutes of moderate-intensity exercise. We calculated CVR as the change in MCAv from BL to steady-state exercise. We collected farthest distance walked from the electronic medical record. We divided individuals based on average farthest walking distance, (FARhigh or FARlow).
Results Participants (n = 20) were 63 ± 15 years. BL MCAv was not different between groups (p = 0.07). In comparison to FARlow, we report a higher CVR in FARhigh’s ipsilesional (
vs 
, p = 0.02) and contralesional hemisphere (
vs 
, p = 0.04).
Conclusions Physical activity during the hospital stay post-stroke may support cerebrovascular health after discharge. Prospective studies are needed to support this finding.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was an observational study and not a clinical trial.
Funding Statement
Dr. Billinger was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K01HD067318). Dr. Whitaker, Ms. Morton, and Ms. Henry received support by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD057850). Ms. Morton received a Student Scholarship in Cerebrovascular Disease and Stroke from the American Heart Association. REDCap at KU Medical Center is supported by the Clinical and Translational Science Award (UL1TR000001) from the National Center for Research Resources and National Center for Advancing Translational Science. The National Center for Advancing Translational Science awarded to the University of Kansas Frontiers the Clinical and Translational Science Institute (UL1TR002366). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board: This study was approved by the University of Kansas Medical Center Human Subjects Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request to corresponding author.
